stockrow
Saturday 7 November 2026
Export KPTI’s income statement to Excel — free account
Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024.
- Revenue
- −11.9%
- EPS
- +46.3%
- Free cash flow
- −33.3%
- Total debt
- +36.6%
Quarter to June 2026, against a year earlier
0.05
0.01
−16.67%
Follow KPTI
Alert me
Karyopharm Therapeutics Inc. (KPTI) P/E ratio
Karyopharm Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPTI Karyopharm Therapeutics Inc. | n/m |
| OGEN Oragenics, Inc. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.2× |
| ABPO Abpro Holdings Inc. compare | 0.5× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)